The Evolution of Site Selection

ABSTRACT

Whether it was recognition, for a very long time pre-pandemic, that industry needed new ways to recruit and retain patients, or the success realized last year during the global SARS-CoV-2 vaccine trials, when pharma said we have no choice but to adopt in situ-or both reasons-the clinical trial industry is doing a 180, site-selection speaking. Syneos has the clinical trial networks;Elligo has access to Cerner and other EHR systems, said Maria Fotiu, executive vice president, decentralized solutions, Syneos Health. Healthcare, said Keith Fern, vice president, corporate development, Elligo, has become a heterogenous business. According to the Curebase website, its technology propelled the start of a COVID trial in two weeks.